Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Email this article to a Colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to My Articles & Searches Download to citation manager Citing Articles via HighWire Citing Articles via Google Scholar Articles by Keck, P. E. Articles by the Aripiprazole Study Group, Search for Related Content PubMed Citation Articles by Keck, P. E., Jr. Articles by the Aripiprazole Study Group, Bipolar Disorder Atypical Neuroleptics

A Placebo-Controlled, Double-Blind Study of the Efficacy and Safety of Aripiprazole in Patients With Acute Bipolar Mania

OBJECTIVE: The authors compared the efficacy and safety of aripiprazole, a novel antipsychotic, to placebo for treatment of patients in an acute manic or mixed episode of bipolar disorder. METHOD: This 3-week, multicenter, double-blind study randomly assigned 262 bipolar disorder patients in an acute manic or mixed episode to aripiprazole, 30 mg/day (reduced to 15 mg/day if needed for tolerability), or placebo. Patients remained hospitalized for at least 2 of the weeks. The primary efficacy measure was mean change from baseline in total score on the Young Mania Rating Scale; response was defined as a decrease in score of 50%. RESULTS: Aripiprazole produced statistically significant mean improvements in total score on the Young Mania Rating Scale compared with placebo (–8.2 versus –3.4, respectively) and produced a significantly higher response rate (40% versus 19%). For key efficacy variables (response per Young Mania Rating Scale; Clinical Global Impression—Bipolar Version scores for severity of illness [mania] and change from preceding phase [mania]), aripiprazole separated from placebo by day 4. The completion rate was significantly higher with aripiprazole than with placebo (42% versus 21%). Discontinuations due to adverse events did not differ significantly between the aripiprazole and placebo groups. There were no significant changes in body weight versus placebo, and aripiprazole was not associated with elevated serum prolactin or QTc prolongation. CONCLUSIONS: Aripiprazole had significantly greater efficacy than placebo for the treatment of bipolar disorder patients in acute manic or mixed episodes and was safe and well tolerated in this randomized controlled trial.

This article has been cited by other articles:

				J. J. Guo, P. E. Keck, H. Li, and N. C. Patel Treatment Costs Related to Bipolar Disorder and Comorbid Conditions Among Medicaid Patients With Bipolar Disorder Psychiatr Serv, August 1, 2007; 58(8): 1073 - 1078. [Abstract] [Full Text] [PDF]

				H. Scherk, F. G. Pajonk, and S. Leucht Second-Generation Antipsychotic Agents in the Treatment of Acute Mania: A Systematic Review and Meta-analysis of Randomized Controlled Trials Arch Gen Psychiatry, April 1, 2007; 64(4): 442 - 455. [Abstract] [Full Text] [PDF]

				R. M. A. Hirschfeld Guideline Watch (November 2005): Practice Guideline for the Treatment of Patients with Bipolar Disorder, 2nd Edition Focus, January 1, 2007; 5(1): 34 - 39. [Abstract] [Full Text] [PDF]

				Bibliography BIPOLAR DISORDER Focus, January 1, 2007; 5(1): 40 - 43. [Full Text] [PDF]

				G. Sachs, R. Sanchez, R. Marcus, E. Stock, R. Mcquade, W. Carson, N. Abou-Gharbia, C. Impellizzeri, S. Kaplita, L. Rollin, et al. Aripiprazole in the treatment of acute manic or mixed episodes in patients with bipolar I disorder: a 3-week placebo-controlled study J Psychopharmacol, July 1, 2006; 20(4): 536 - 546. [Abstract] [PDF]

				M. K. Nickel, M. Muehlbacher, C. Nickel, C. Kettler, F. P. Gil, E. Bachler, W. Buschmann, N. Rother, R. Fartacek, C. Egger, et al. Aripiprazole in the Treatment of Patients With Borderline Personality Disorder: A Double-Blind, Placebo-Controlled Study Am J Psychiatry, May 1, 2006; 163(5): 833 - 838. [Abstract] [Full Text] [PDF]

				P. A Marken and R. W Pies Emerging Treatments for Bipolar Disorder: Safety and Adverse Effect Profiles Ann. Pharmacother., February 1, 2006; 40(2): 276 - 285. [Abstract] [Full Text] [PDF]

				E. Vieta, M. Bourin, R. Sanchez, R. Marcus, E. Stock, R. McQuade, W. Carson, N. Abou-Gharbia, R. Swanink, T. Iwamoto, et al. Effectiveness of aripiprazole v. haloperidol in acute bipolar mania: Double-blind, randomised, comparative 12-week trial The British Journal of Psychiatry, September 1, 2005; 187(3): 235 - 242. [Abstract] [Full Text] [PDF]

				R. WAHL and R. OSTROFF Reversal of Symptomatic Hyperprolactinemia by Aripiprazole Am J Psychiatry, August 1, 2005; 162(8): 1542 - 1543. [Full Text] [PDF]

				K. C Coley Aripiprazole prescribing and continuation rates during psychiatric hospitalization Ann. Pharmacother., July 1, 2005; 39(7): 1367 - 1368. [Full Text] [PDF]

				K. JAGADHEESAN and D. MUIRHEAD Aripiprazole for Acute Bipolar Mania Am J Psychiatry, October 1, 2004; 161(10): 1926 - 1927. [Full Text] [PDF]

				R. M.A. Hirschfeld, P. E. Keck Jr., M. Kramer, K. Karcher, C. Canuso, M. Eerdekens, and F. Grossman Rapid Antimanic Effect of Risperidone Monotherapy: A 3-Week Multicenter, Double-Blind, Placebo-Controlled Trial Am J Psychiatry, June 1, 2004; 161(6): 1057 - 1065. [Abstract] [Full Text] [PDF]

				J. P Kelleher Aripiprazole is effective against the symptoms of schizophrenia and schizoaffective disorder Evid. Based Ment. Health, February 1, 2004; 7(1): 13 - 13. [Full Text] [PDF]

Get information about faster international access.

Privacy Policy

Copyright © 2003 American Psychiatric Association. All rights reserved.

Home | Search | Current Issue | Past Issues | Subscribe | All APPI Journals | Help | Contact Us